Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

136 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Mutant NPM1 Maintains the Leukemic State through HOX Expression.
Brunetti L, Gundry MC, Sorcini D, Guzman AG, Huang YH, Ramabadran R, Gionfriddo I, Mezzasoma F, Milano F, Nabet B, Buckley DL, Kornblau SM, Lin CY, Sportoletti P, Martelli MP, Falini B, Goodell MA. Brunetti L, et al. Among authors: sportoletti p. Cancer Cell. 2018 Sep 10;34(3):499-512.e9. doi: 10.1016/j.ccell.2018.08.005. Cancer Cell. 2018. PMID: 30205049 Free PMC article.
Therapeutic strategies and treatment sequencing in patients with chronic lymphocytic leukemia: An international study of ERIC, the European Research Initiative on CLL.
Chatzikonstantinou T, Scarfò L, Minga E, Karakatsoulis G, Chamou D, Kotaskova J, Iacoboni G, Demosthenous C, Albi E, Alcoceba M, Al-Shemari S, Aurran-Schleinitz T, Bacchiarri F, Chatzileontiadou S, Collado R, Davis Z, de Deus Santos MD, Dimou M, Dmitrieva E, Donaldson D, Dos Santos G, Dreta B, Efstathopoulou M, El-Ashwah S, Enrico A, Frygier A, Galimberti S, Galitzia A, Gimeno E, Guarente V, Guieze R, Harrop S, Hatzimichael E, Herishanu Y, Hernández-Rivas JÁ, Jaksic O, Kalicińska E, Laribi K, Karakus V, Kater AP, Kho B, Kislova M, Konstantinou Ε, Koren-Michowitz M, Kotsianidis I, Kubova Z, Labrador J, Lad D, Laurenti L, Longval T, Lopez-Garcia A, Marquet J, Maslejova S, Mayor-Bastida C, Mihaljevic B, Milosevic I, Miras F, Moia R, Morawska M, Nath UK, Navarro-Bailón A, Olivieri J, Panovska-Stavridis I, Papaioannou M, Pierie C, Puiggros A, Reda G, Rigolin GM, Ruchlemer R, Schipani M, Schiwitza A, Shen Y, Shokralla T, Simkovic M, Smirnova S, Soliman DSA, Stilgenbauer S, Tadmor T, Tomic K, Tse E, Vassilakopoulos T, Visentin A, Vitale C, Vrachiolias G, Vukovic V, Walewska R, Xu Z, Yagci M, Yañez L, Yassin M, Zuchnicka J, Oscier D, Gozzetti A, Panagiotidis P, Bosch F, Sportoletti P See abstract for full author list ➔ Chatzikonstantinou T, et al. Among authors: sportoletti p. Hemasphere. 2024 Sep 17;8(9):e70004. doi: 10.1002/hem3.70004. eCollection 2024 Sep. Hemasphere. 2024. PMID: 39290716 Free PMC article. No abstract available.
COVID-19 in patients with Chronic Lymphocytic Leukemia treated with venetoclax: what is the role of anti-CD20 antibody?
Autore F, Visentin A, Deodato M, Vitale C, Galli E, Fresa A, Fazzi R, Sanna A, Olivieri J, Scortechini I, Del Principe MI, Sportoletti P, Innocenti I, Coscia M, Tedeschi A, Trentin L Prof, Candoni A, Busca A, Pagano L, Laurenti L. Autore F, et al. Among authors: sportoletti p. Blood Adv. 2024 Oct 25:bloodadvances.2024013792. doi: 10.1182/bloodadvances.2024013792. Online ahead of print. Blood Adv. 2024. PMID: 39454205 No abstract available.
Lymphadenopathy as a predictor of progression during venetoclax treatment in chronic lymphocytic leukemia. A campus chronic lymphocytic leukemia study.
Autore F, Innocenti I, Reda G, Visentin A, Vitale C, Piciocchi A, Fresa A, Leone MMA, Farina L, Quaresmini G, Baratè C, Giordano A, Ferrari A, Angeletti I, De Paolis MR, Malerba L, Chiurazzi F, Loseto G, Catania G, Sportoletti P, Scortechini I, Moia R, Gentile M, Rigolin GM, Mattiello V, Gattei V, Coscia M, Trentin L, Foà R, Cuneo A, Laurenti L. Autore F, et al. Among authors: sportoletti p. Hematol Oncol. 2023 Dec;41(5):877-883. doi: 10.1002/hon.3199. Epub 2023 Jul 1. Hematol Oncol. 2023. PMID: 37392141
XPO1 mutations identify early-stage CLL characterized by shorter time to first treatment and enhanced BCR signalling.
Moia R, Terzi di Bergamo L, Talotta D, Bomben R, Forestieri G, Spina V, Bruscaggin A, Cosentino C, Almasri M, Dondolin R, Bittolo T, Zucchetto A, Baldoni S, Del Giudice I, Mauro FR, Maffei R, Chiarenza A, Tafuri A, Laureana R, Del Principe MI, Zaja F, D'Arena G, Olivieri J, Rasi S, Mahmoud A, Al Essa W, Awikeh B, Kogila S, Bellia M, Mouhssine S, Sportoletti P, Marasca R, Scarfò L, Ghia P, Gattei V, Foà R, Rossi D, Gaidano G. Moia R, et al. Among authors: sportoletti p. Br J Haematol. 2023 Nov;203(3):416-425. doi: 10.1111/bjh.19052. Epub 2023 Aug 14. Br J Haematol. 2023. PMID: 37580908
Real-World Outcome of Treatment with Single-Agent Ibrutinib in Italian Patients with Chronic Lymphocytic Leukemia: Final Results of the EVIdeNCE Study.
Mauro FR, Scalzulli PR, Scarfò L, Minoia C, Murru R, Sportoletti P, Frigeri F, Albano F, Di Renzo N, Sanna A, Laurenti L, Massaia M, Cassin R, Coscia M, Patti C, Pennese E, Tafuri A, Chiarenza A, Galieni P, Perbellini O, Selleri C, Califano C, Ferrara F, Cuneo A, Murineddu M, Palumbo G, Scortechini I, Tedeschi A, Trentin L, Varettoni M, Pane F, Liberati AM, Merli F, Morello L, Musuraca G, Tani M, Ibatici A, Regazzoni G, Di Candia M, Palma M, Arienti D, Molica S. Mauro FR, et al. Among authors: sportoletti p. Cancers (Basel). 2024 Mar 20;16(6):1228. doi: 10.3390/cancers16061228. Cancers (Basel). 2024. PMID: 38539561 Free PMC article.
Management of infections for patient treated with ibrutinib in clinical practice.
Baratè C, Scortechini I, Ciofini S, Picardi P, Angeletti I, Loscocco F, Sanna A, Isidori A, Sportoletti P. Baratè C, et al. Among authors: sportoletti p. Front Oncol. 2024 Sep 10;14:1428464. doi: 10.3389/fonc.2024.1428464. eCollection 2024. Front Oncol. 2024. PMID: 39319061 Free PMC article. Review.
A pro-inflammatory environment in bone marrow of Treg transplanted patients matches with graft-versus-leukemia effect.
Guardalupi F, Sorrentino C, Corradi G, Giancola R, Baldoni S, Ulbar F, Fabi B, Andres Ejarque R, Timms J, Restuccia F, Santarone S, Accorsi P, Sportoletti P, De Falco F, Rosati E, Carotti A, Falzetti F, Velardi A, Martelli MF, Kordasti S, Pierini A, Ruggeri L, Di Ianni M. Guardalupi F, et al. Among authors: sportoletti p. Leukemia. 2023 Jul;37(7):1572-1575. doi: 10.1038/s41375-023-01932-x. Epub 2023 Jun 7. Leukemia. 2023. PMID: 37286785 Free PMC article. No abstract available.
Venetoclax infectious risk score to identify patients with chronic lymphocytic leukemia at high infectious risk during venetoclax treatment: A multicenter SEIFEM study.
Autore F, Visentin A, Deodato M, Vitale C, Galli E, Fresa A, Fazzi R, Sanna A, Olivieri J, Scortechini I, Del Principe MI, Sportoletti P, Schiattone L, Maschio N, Facchinelli D, Marchesi F, Coscia M, Tedeschi A, Trentin L, Innocenti I, Candoni A, Busca A, Pagano L, Laurenti L. Autore F, et al. Among authors: sportoletti p. Am J Hematol. 2024 May;99(5):982-984. doi: 10.1002/ajh.27247. Epub 2024 Feb 11. Am J Hematol. 2024. PMID: 38343033 No abstract available.
Exploring the administrative burden faced by hematologists: a comprehensive study in Italy.
Petruzzelli D, Vignetti M, Trasarti S, Sportoletti P, Torre SD, Cairoli R, Leone FPC, Pompilio G, Gullì M, Hajdukova EB, Integlia D. Petruzzelli D, et al. Among authors: sportoletti p. Glob Reg Health Technol Assess. 2024 Jul 3;11:161-168. doi: 10.33393/grhta.2024.3042. eCollection 2024 Jan-Dec. Glob Reg Health Technol Assess. 2024. PMID: 38979549 Free PMC article.
136 results